G-BA backs Bayer's Stivarga

Germany's Federal Joint Committee (G-BA) issued a final benefit assessment that found Stivarga regorafenib from Bayer AG (Xetra:BAYN) has "marginal" additional benefit vs. best supportive care (BSC) t...